🏢 What kind of company is Merck?

Merck (MRK) is a global large-cap pharmaceutical company founded in the United States in 1891. Headquartered in the United States, it operates oncology, vaccines, immunology, and animal-health businesses as its core areas. As a member of the Dow Jones Industrial Average, it holds a representative position among major U.S. pharmaceutical stocks.

Its businesses include immuno-oncology drugs such as Keytruda, vaccines including Gardasil and new vaccine candidates, general medicines for cardiovascular disease, diabetes, and infections, and animal-health products for livestock and companion animals. It holds a leading position in the global immuno-oncology category.

💰 How does Merck make money?

Keytruda accounts for a core share of Merck's revenue, while the vaccine business, including Gardasil, is expanding as a diversification-driven growth pillar. The animal-health segment provides a stable revenue base that is separate from the cycle of human medicines. Because of its global revenue structure, the company also faces fluctuations in translated revenue caused by foreign-exchange movements. Strengthening the pipeline through research-and-development investment and acquisitions is a central challenge as Merck works to fill the potential revenue gap after Keytruda's patent expiration.

📐 Merck's market capitalization and company size

Its market capitalization is $320.6B, and it has 75,000명 employees.

As a mega-cap pharmaceutical stock ranked among the world's largest companies by market capitalization, Merck belongs to the same large-pharmaceutical peer group as PFE, LLY, AZN, BMY, and ABBV. Supported by stable operating cash flow, it conducts share repurchases and maintains consistent dividend returns, making it a frequent holding in global healthcare dividend portfolios.

📈 Merck's outlook and stock performance

Expansion of Keytruda's indications and its next-generation oncology and antibody-drug conjugate pipeline are the key long-term drivers. The global expansion of vaccines such as Gardasil and growth in the animal-health business also support revenue diversification, while Merck continues efforts to strengthen its pipeline through acquisitions. Near-term variables include the timeline for Keytruda's long-term patent expiration, drug-price negotiations in the United States and Europe, foreign-exchange movements, and volatility in major clinical-trial results.

• Expansion of Keytruda's indications and its next-generation oncology pipeline
• Global expansion of the vaccine lineup
• Pipeline strengthening through acquisitions

⚔️ Merck's key competitive strengths and risks

Its leading position in immuno-oncology and a diversified business portfolio are key strengths, while Keytruda's patent expiration and drug-price regulation are major risks.

🔄 Merck's competitors and related stocks

Direct competitors in the global large-pharmaceutical category include BMY in immuno-oncology and oncology, LLY in oncology and diabetes, PFE across a broad range of businesses, AZN in oncology and rare diseases, and ABBV in immunology and autoimmune disease. Among related stocks, REGN in antibody-based new drugs and BIIB in neurological and antibody therapies are also compared as adjacent peers. BMY, LLY, PFE, AZN, and ABBV compete directly in the same treatment areas, while REGN and BIIB are considered related groups that often move alongside the healthcare sector.

✅ Merck investor checklist

These are the key points to review when investing in Merck. Key near- and medium-term variables include the expansion of Keytruda's indications, the timeline for its long-term patent expiration, the pace of vaccine-line expansion, and the drug-pricing regulatory environment. Investors should also monitor efforts to strengthen the pipeline.

Keytruda's long-term patent expiration is the central near- and medium-term risk. Tighter drug-price regulation, volatility in major clinical-trial results, and foreign-exchange exposure in global revenue may also create potential volatility. How Merck strengthens its pipeline through acquisitions will be a decisive factor for its long-term revenue trend.

Merck is a mega-cap pharmaceutical company that continues to provide stable dividend returns, supported by its leadership in immuno-oncology and diversification across vaccines and animal health. However, patent expiration, drug pricing, and clinical-trial volatility remain key variables, so phased buying and a long-term perspective are recommended.